Methotrexate Sodium Shortage As ELTP Gets Approved

"Up there - once again - with the big boys."

Methotrexate Sodium is a drug designed to fight cancer and is currently backlogged with no guarantee for fulfillment in the near-term.  This comes as Elite recently announced the FDA green-lit their ~~knockoff~~ nay, generic version.  

On May 20, 2024, in a press release, Elite Pharmaceuticals, Inc., or Elite, reported that it received approval from the US Food and Drug Administration (FDA) on May 16, 2024 for a generic version of Methotrexate Sodium (“Methotrexate”) 2.5 mg tablets. Methotrexate belongs to a class of drugs known as antimetabolites and will be sold under the Elite Laboratories, Inc. label.

There's a description of this shortage which includes the [then known] alternatives available:

Available Products

• Methotrexate injection, Fresenius Kabi, 25 mg/mL, 10 mL (with preservative) vial, 1 count, NDC 63323-0123-10
• Methotrexate, Fresenius Kabi, 1 gram, vial, 1 count, NDC 63323-0122-50
• Methotrexate injection, Pfizer, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 61703-0408-41
• Methotrexate injection, Teva, 25 mg/mL, 10 mL preservative-free vial, 1 count, NDC 00703-3675-01
• Methotrexate injection, Teva, 25 mg/mL, 40 mL preservative-free vial, 1 count, NDC 00703-3678-01

$ELTP's announcement came only days later, but it is up there - once again - with the big boys.

ASHP'S ARTICLE HERE

2024 ELTP Has A Different Feel

 Still strong but definitely a different management style.  The trajectory also looks improved from the past couple years.  Don't call it a resurgence.

New Day - Can We Expect More of an Upswing?

 

Investor News Update: Elite Pharmaceuticals (Ticker: $ELTP)

Date: [07/27/2023]

Note:  This is an exclusive report provided by https://elitepharmaceuticals.blogspot.com/, not an official source for $ELTP updates, but a helpful tool nonetheless. 

---

Hello all!

Here's an update on Elite Pharmaceuticals ($ELTP) and its performance

Company Overview: Elite Pharmaceuticals is a dynamic and innovative pharmaceutical company dedicated to developing and commercializing high-quality, generic, and specialty pharmaceutical products. The company's primary focus is on controlled-release drug delivery technologies, abuse-deterrent formulations, and products with high barriers to entry.

Recent Developments:

1. FDA Approval Milestone: One of the most significant recent achievements for Elite Pharmaceuticals is the FDA approval of a new drug from their product pipeline. The approval marks a major milestone for the company and opens up new revenue streams, enhancing its position in the pharmaceutical market.

2. Strategic Partnerships: Elite Pharmaceuticals has been actively pursuing strategic partnerships with leading pharmaceutical companies to expand its product portfolio and market reach. These collaborations are expected to provide the company with greater access to distribution networks and complementary expertise, resulting in accelerated growth and increased market presence.

3. Financial Performance: In its latest financial report, Elite Pharmaceuticals has demonstrated strong financial performance, exceeding market expectations. Increased sales revenue, prudent cost management, and favorable market conditions have contributed to the company's impressive results, instilling confidence in investors and analysts alike.

4. R&D Advancements: The company's commitment to research and development remains unwavering. Elite Pharmaceuticals continues to invest in cutting-edge drug delivery technologies and novel formulations. These ongoing advancements not only bolster their existing product lines but also position the company for future growth and competitiveness in the pharmaceutical landscape.

5. Market Expansion: Elite Pharmaceuticals has successfully penetrated new markets, both domestically and internationally. This expansion has opened up avenues for increased sales and has diversified the company's revenue streams, reducing dependency on any one market.

Current Price Details:

• Last Price - At the Close: $0.0432

Performance Metrics:

• UP 46% Since the Beginning of the Year: Elite Pharmaceuticals ($ELTP) has demonstrated impressive growth, with its stock price surging by 46% since the start of the year. This significant increase showcases the company's ability to capitalize on market opportunities and its strong performance in the pharmaceutical sector.

• UP 15% Above 20-day SMA: The stock of Elite Pharmaceuticals is currently trading at a notable 15% above its 20-day Simple Moving Average (SMA). This indicates positive momentum and suggests that the company's share price has been trending higher in the short term.

• UP 29% Above 200-day SMA: Furthermore, Elite Pharmaceuticals' stock is performing exceptionally well in the long term, with a remarkable increase of 29% above its 200-day Simple Moving Average (SMA). This indicates sustained upward momentum and reflects the company's consistent growth over an extended period.

Outlook and Analysis:

Looking ahead, Elite Pharmaceuticals appears to be on a solid trajectory. With recent FDA approvals, strategic partnerships, strong financials, and a robust pipeline of products, the company is well-positioned for sustained growth and long-term success. Furthermore, their focus on innovation and commitment to R&D could potentially yield breakthrough products in the near future.

However, it is essential to acknowledge that the pharmaceutical industry is subject to regulatory challenges, market fluctuations, and competitive pressures. As such, prudent investors should exercise due diligence and stay updated on the company's quarterly reports, announcements, and industry developments.

Conclusion:

Elite Pharmaceuticals ($ELTP) has demonstrated its commitment to excellence in the pharmaceutical sector, and its recent achievements underscore the potential for further growth. As an investor, it is essential to assess your risk tolerance and investment strategy before considering adding this stock to your portfolio. While the company's prospects appear promising, the market always carries inherent risks, and professional financial advice is recommended.

Please note that this update is for informational purposes only and not a solicitation to buy or sell securities. We encourage you to conduct thorough research and seek advice from a qualified financial advisor before making any investment decisions.

Thank you for your attention, and we will keep you informed about any further developments regarding Elite Pharmaceuticals ($ELTP) as they arise.

Best regards,

ELTP Blog,  https://elitepharmaceuticals.blogspot.com

Elite - Echos

 Damn Mikah.  Hakim.  Mikah. Hakim. Fkn do something.

Longs Want $ELTP to Sell!

 But what if greedy boomer/senior, Hakim, sells to Mikah?  

This is where shit always go haywire - and all I'm doing is trying to recoup some losses and not make too much wave  action.  I get it, market, the bad guys have already exited stage right and and there's little chance for this market to truly rebound.  In my portfolio, $ELTP is the one stock that needs to blow up - it needs to be sold -  but not to Hakim's mirror image.  What a greedy motherfucker he has turned out to be .... 9 or 10 years of trying to establish a foot in for a position that's marginal, and $eltp has always be a consistent grinder during these years.  What's the plan, Hakim?  Just sell your heap in a way that'll benefit all of investors.  Save the internet, share a piece of saving mankind with a swing of thee bat.  Do the right thing

Elite Pharmaceuticals Gets A Decent Review (March, 2022)

Well, I'm a little slow to this because the market has been tricky enough without bringing Elite into the mix, but since March 2022, when this review ran on youtube's RunningRobert's page, Elite has bucked at years long bearish movement. Last week Elite's stock began to bounce just enough for me to check out what I have missed recently. Adderall was a really great shift in the right direction for Elite and they are just a tad profitable. Anyway I share a lot of the sentiment in this video, and more similar reads could pop up if this really is a move higher for the stock.

ELTP Continues to Bewilder

Remember the days when the transparency and  communication were at all-time high levels for Elite?   They always seem just a step from being a marketing blitz away from getting where they should be, in the .24 cent range where they once perched. 

They sure have pulled that rug out on that and have made it all about this Hakim liar. 

It's sad because they were once surefooted, but now they are just little pathetic and stagnant.  For the love of all that is holy, Mikah Hakim Rat whatever you wanna call him should MOVE.  Don't allow whatever opportunities to be squandered and rather do the set of steps required to get us all to where you were once so confident we'd be by now.